Scientific Program
by July 2026
The detailed scientific program is currently being set up and will be available in its preliminary version shortly.
The preliminery program for GUF 2026 is now available.
Please click the button below to view the current program and find detailed information on the sessions and schedule.
Wednesday, 4 December 2024
08:00-09:45
Registration
09:45-10:00
Welcome, introduction and objectives
Luis Ensina, Ana Gimenéz-Arnau, Emek Kocatürk, Torsten Zuberbier
Keynote lecture session I: Pathophysiology of CSU
10:00-10:25
Chronic spontaneous urticaria: Update on pathophysiology
Michihiro Hide, Sarbjit Saini
10:25-10:50
Non-IgE-mediators and neurogenic activation of mast cells
Martin Metz,Young Min Ye
Oral presentation session I: Aetiopathogenesis of urticaria, differential diagnosis, comorbidities and diagnostic approaches
10:50-10:59
10:59-11:08
11:08-11:17
11:17-11:26
11:26-11:35
OP.001 | The role of T-cell-mast-cell cross talk and proximity in the pathogenesis of chronic spontaneous urticaia
Elias Toubi
OP.002 | Relevance of the basophil activation test in a cohort of 240 patients with chronic spontaneous urticaria
David Pesqué
OP.003 | Development of a rapid and portable test for the measurement of anti-TPO IgE in clinical practice. Proof of concept.
Jorge Sanchez
OP.004 | Depletion of mast cells with barzolvolimab, an anti-KIT antibody, does not affect mast cell progenitor numbers or function
Sherezade Moñino-Romero
OP.005 | CD300 receptor: A new target in the pathogenesis of autoimmune urticaria?
Ozge Sevil Karstarli Bakay
11:36-12:00
Coffee break
EMBRN session: The biology of mast cells and basophils and their role in health and disease
12:00-12:05
EMBRN introduction
Francesca Levi-Schaffer
Frank Siebenhaar
12:05-12:20
The evolving story of the allergic effector unit
Francesca Levi-Schaffer
12:20-12:35
Mast cells and tissue infiltrating immune cells
Stefan Frischbutter
12:35-12:50
Mast cells in the skin: enemies driving inflammation or defenders of integrity?
Anne Dudeck
12:50-12:55
Summary
Francesca Levi-Schaffer
Frank Siebenhaar
12:55-13:55
Sponsored symposium
13:55-14:25
Lunch break
Keynote lecture session II: Endotypes and biomarkers of CU
14:25-14:50
Endotypes of CSU – What we know and what we don´t know
Riccardo Asero, Pavel Kolkhir
14:50-15:15
Biomarkers of CU clinical behavior and therapy response to available treatments
Luis Ensina, Desire Larena Linnemann
Oral presentation session II: Urticaria treatments, predictors of response and biomarkers in CU
15:15-15:24
15:24-15:33
15:33-15:42
15:42-15:51
15:51-16:00
OP.006 | EVO756, an oral MRGPRX2 antagonist, is well-tolerated and demonstrates target engagement: Topline results from a phase 1 study
Sarbjit S. Saini
OP.007 | Prognostic value of novel in-vitro variables for severe CSU responding and not responding to omalizumab
Riccardo Asero
OP.008 | Barzolvolimab shows profound efficacy and favorable safety over 52 weeks in patients with chronic spontaneous urticaria
Martin Metz
OP.009 | Rilzabrutinib reduces severity of weekly urticaria activity score in patients with chronic spontaneous urticaria in RILECSU phase 2 trial Ana Maria Giménez-Arnau
OP.010 | Safety and efficacy of remibrutinib in japanese patients with chronic spontaneous urticaria (BISCUIT study interim analysis)
Koremasa Hayama
14:49-14:58
OP.007 PREDICT-CU: Predicting time to clinical remission in chronic urticaria
Maria-Magdalena Balp (Switzerland)
14:07-15:16
OP.009 Urticaria in patients with suspected mast cell activation syndrome
Fabiana Nunes Oliveira (Brazil)
14:58-15:07
OP.008 Remibrutinib inhibits mastcell and basophil activation in chronic urticaria independently of FcεR1 expression
Ana Giménez-Arnau (Spain)
14:16-15:25
OP.010 In chronic spontaneous urticaria, fever, pain and malaise are common and linked to active and uncontrolled disease: Results from the Chronic Urticaria Registry (CURE)
Polina Pyatilova (Germany)
16:00-16:35
Coffee break
Poster walks and poster session
16:35-17:35
Poster session | Poster walks
In recognition of the great person, Marcus Maurer
17:35-18:35
The history of modern urticaria and a tribute to Marcus Maurer
Oral Presentation Session III: Urticaria treatments and predictors of response
16:20-16:40
What’s new?
16:40-17:25
Oral Presentations
17:49-17:58
OP.012 Long-term safety of remibrutinib in CSU patients: Phase 2b study
Ana Giménez-Arnau (Spain)
17:58-18:07
OP.013 Dupilumab Efficacy in Patients with Chronic Spontaneous Urticaria with Comorbidities
Marcus Maurer (Germany)
18:07-18:16
OP.014 Cold urticaria patients achieve complete response with 1.5 mg/kg barzolvolimab
Dorothea Terhorst-Molawi (USA)
18:16-18:25
OP.015 Elevated levels of soluble FcεRI as a biomarker of early and good response to omalizumab treatment in chronic spontaneous urticaria
Sherezade Moñino-Romero (Germany)
18:25-18:34
OP.016 Differences between pediatric and adult urticaria: patient characteristics, treatment response and indicators of response
Sinem Ornek Ozdemir (Turkey)
18:34-18:43
OP.017 Autoimmunity and low IgE in CSU: a prospective analysis
David Pesqué (Spain)
18:43-18:52
OP.018 Anti-TPO/total IgE ratio – biomarker for omalizumab response prediction in CSU
Rita Brás (Portugal)
18:35
Scientific dinner
Thursday, 5 December 2024
07:15-08:30
Registration
08:30-08:35
Welcome and summary day 1
Torsten Zuberbier
UCARE session
08:35-09:05
UCARE update Emek Kocatürk
LevelUp Iman Nasr
4U Maryam Al-Nesf Al-Mansouri
CURE Karsten Weller
CRUSE Sophia Neisinger
09:05-09:38
Current UCARE Scientific projects
Pavel Kolkhir
Sabine Altrichter
Emek Kocatürk
Polina Pyatilova
Pavel Kolkhir
Melba Munoz-Roldan
Murat Türk
Yikui Xiang
Ivan Cherrez-Ojeda
Beatrice Martinez Zugaib Abdalla
Petra Staubach
09:38-09:56
Upcoming projects
Jennifer Donnelly
Hanna Bonnekoh
Lea Alice Kiefer
Thomas Buttgereit
Maryam Khoshkhui
Simon Francis Thomsen
Lea Alice Kiefer
Aiste Ramanauskaite
Ragıp Ertaş
14:48-15:01
Importance of the complement test in patients with angioedema taking ACE inhibitor
Henriette Farkas (Hungary)
15:01-15:14
The use of anti-IgE therapy to define idiopathic non-histaminergic angioedema
Jason Fok (Australia)
15:14-15:27
Estrogen triggering non-hereditary Angioedema
Anete Grumach (Brazil)
15:27-15:40
ACARE projects and activities
Markus Magerl (Germany)
Oral presentation session III: Urticariological highlights
09:56-10:05
10:05-10:14
10:14-10:23
10:23-10:32
10:32-10:41
OP.011 | Efficacy and safety of dupilumab in chronic spontaneous urticaria – An exploratory phase 2 investigator-initiated trial
Martin Metz
OP.012 | Efficacy, predictors of response and safety of H1 AH in the treatment of CU in children
Larissa Brandão
OP.013 | Differential susceptibility of hair color changes after anti-KIT antibody, barzolvolimab in patients with chronic inducible urticaria
Melba Munoz
OP.014 | Evaluation of disease severity metrics in pediatric patients with chronic spontaneous urticaria
Moshe Ben Shoshan
OP.015 | Urticaria and its shadows: What to measure beyond the skin
Ivan Cherrez-Ojeda
09:14-09:23
OP.020 Treatment with MRGPRX2 Antagonist EP262 Potently Inhibits Mast Cell Degranulation
Veena Viswanath (USA)
09:23-09:32
OP.021 Remibrutinib improves CSU in patients with low or high IgE
Michihiro Hide (Japan)
09:32-09:41
OP.022 Anti-IL-23 treatment in patients with omalizumab-refractory chronic spontaneous urticaria – a case series
Hanna Bonnekoh (Germany)
09:41-09:50
OP.023 Omalizumab drug survival for chronic urticaria – the DruSO-CU UCARE study
Reineke Soegiharto (The Netherlands)
09:50-09:59
OP.024 CRUSE – What the first 100 days have taught us
Sophia Neisinger (Germany)
10:41-11:10
Coffee break
ACARE session: Recurrent angioedema
11:10-11:20
Intro about ACARE and welcome
Henriette Farkas
Markus Magerl
11:20-11:40
Predictive model to differentiate chronic histaminergic angioedema and chronic spontaneous urticaria with angioedema
Ana Lainez
11:40-12:00
Update on ACARE projects
Ivan Cherrez-Ojeda
Thomas Buttgereit
Carolina Vera
Philip Li
12:00-12:25
DANCEing with angioedema
Thomas Buttgereit
12:25-12:30
Summary
Henriette Farkas
Markus Magerl
12:30-13:30
Sponsored symposium
13:30-14:20
Lunch break
The Global Allergy and Asthma Excellence Network session
14:20-14:50
The Global Allergy and Asthma Excellence Network general assembly
Torsten Zuberbier
Spotlight on chronic inducible urticaria session
14:50-15:00
Cold urticaria
Mojca Bizjak
15:00-15:10
Cholinergic urticaria
Sabine Altrichter
15:10-15:20
Symptomatic dermographism
Daria Fomina
15:20-15:30
Solar urticaria
Atsushi Fukunaga
Oral presentation session IV: Remission, relapse, disease modification, urticarial march – The nomenclature of CSU
15:30-15:39
15:39-15:48
15:48-15:57
15:57-16:06
OP.016 | Characterization of pathomechanisms of acute and chronic spontaneous urticaria
Hanna Bonnekoh
OP.017 | Side effects of omalizumab in patients with chronic urticaria: a long-term multi-centre real-world study
Reineke Soegiharto
OP.018 | Chronic spontaneous urticaria comes with increased mortality: A real world cohort study
Pavel Kolkhir
OP.019 | A survey on prognosis of acute urticaria of 1075 patients in ten clinics in Hiroshima
Rina Kamigaki
16:06-16:20
Coffee break
Keynote lecture session III: The future of urticariology
16:20-16:33
Unmet needs in research and management of urticaria
Torsten Zuberbier
16:33-16:46
Best practice for patient management
Jonathan Bernstein
16:46-16:59
Future treatment options for CU
Ana Maria Gimenez-Arnau
16:59-17:19
Closing remarks / prizes / good byes
Luis Ensina, Ana Gimenéz-Arnau, Emek Kocatürk, Torsten Zuberbier
